BioAtla to be delisted from Nasdaq after appeal fails

What happened

BioAtla, Inc. (BCAB), a San Diego-based biopharmaceutical company developing conditionally active biologics (CAB) for cancer treatment, disclosed in an SEC filing that Nasdaq's Listing Council affirmed an earlier decision to delist the company's common stock. The delisting is based on the company's failure to meet two continued listing requirements: maintaining a minimum $1.00 bid price and having at least $2.5 million in stockholders' equity.

Unless Nasdaq's Board calls the matter for review, trading will be suspended at the open on August 31, 2026, and a Form 25 will be filed to remove the stock from Nasdaq. The company expects its shares to be quoted on the OTC Markets system under the same ticker 'BCAB' after the suspension.

The stock fell 44.75% to close at $1.735 on August 28, 2026, with volume roughly 15.7 times its average, according to market data.

Background

BioAtla had previously disclosed on February 6, 2026, that it received a delisting determination from a Nasdaq Hearings Panel. The company appealed that decision to the Listing Council, which stayed the suspension while it reviewed the case.

On August 26, 2026, the Listing Council notified BioAtla that it had affirmed the original delisting decision. The company is also in an ongoing strategic review process launched in March 2026 to explore options to maximize shareholder value, but no outcome is assured.

What this means

An 8-K is a form companies file with the SEC to announce major events. Item 3.01 is specifically used to notify investors of a delisting or failure to meet listing standards. This filing is the formal disclosure that BioAtla's appeal failed.

Listing rules require companies on Nasdaq to keep their bid price above $1.00 and maintain a minimum stockholders' equity of $2.5 million (or meet alternatives). BioAtla fell short on both, according to the filing. Investors should understand that a delisting removes the stock from Nasdaq's exchange, but does not make the company bankrupt or worthless. Shares typically continue trading over-the-counter (OTC), though often with lower liquidity and visibility.

The Form 25 mentioned is the official document that removes a security from exchange listing and registration. Here, it will be filed after the Board's decision not to review. Normally, after such a filing, the stock moves to OTC Markets, where trading can continue but with less regulatory oversight and potentially wider spreads.

This particular case is about common stock, so it is a significant event for shareholders, unlike delistings of debt securities that are simply being repaid.